Compare Davita Inc (DVA) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Five Below Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Five Below Inc trades at $209.72 (market cap $11.55B). The key difference: Davita Inc and Five Below Inc are close in size by market cap, and Davita Inc is more actively traded (582,204 versus 1,120,554). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Five Below Inc for 46 Days on average.
| DVA | FIVE | |
|---|---|---|
Market Cap | $11.29B | $11.55B |
Volume | 582,204 | 1,120,554 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $262.72 |
52-Week Low | $103.87 | $138.49 |
Typical Hold Time | 113 Days | 46 Days |
Enterprise Value | $24.01B | $12.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Five Below (FIVE) trades at $204.24, down 2.71% today but maintains strong analyst support with 60% buy ratings and a $298.44 consensus price target. The company shows robust revenue growth from $3.88B in 2025 to projected $5.3B in 2026, with earnings beating expectations in three consecutive quarters. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $197.
FIVE presents a compelling growth story with expanding margins and strategic initiatives, though premium valuation (P/E 18.32) and execution risks warrant caution. The stock offers significant upside to analyst targets but faces near-term technical pressure and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
